composition, and ethanol or propylene glycol in an amount of from about 1 to about 15 weight % of the composition;

(c) water in an amount of from about 0.4 to about 3.5 weight % of the composition; and

(d) optionally, a pharmaceutically acceptable surfactant.

4. (twice amended) The composition according to Claim 1 comprising (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) or a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and another HIV protease inhibiting compound selected from the group consisting of:

(2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane;

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);

5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;

1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)- 3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide;

5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;

[1S-[1R-(R-),2S*])-N^1 [3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-

hydroxy-1 -(phenylmethyl)propyl]-2-[(2quinolinylcarbonyl)amino]-butanediamide;



;



;



;


HO
O
H
N
OH
PhS
H
N
O
N
H
H
H
N
H
;


BocHN
OH
H
N
OH
NHBoc
Ph
O
O
N
O
;


H
N
O
N
H
OH
H
N
O
N
H
N
H
Ph
;



; and



;

or a pharmaceutically acceptable salt thereof.

8. (once amended) The composition of Claim 1 wherein the solvent comprises (1) a pharmaceutically acceptable long chain fatty acid in an amount of from about 40 to about 75 weight % of the composition; (2) ethanol or propylene glycol in an amount of from about 3 to about 12 weight % of the composition; and (3) water in an amount of from about 0.4 to about 1.5 weight % of the composition.

9. (once amended) The composition of Claim 1 wherein the solvent comprises (1) oleic acid in an amount of from about 40 to about 75 weight % of the composition; (2) ethanol or propylene glycol in an amount of from about 3 to about 12 weight % of the composition; and (3) water in an amount of from about 0.4 to about 1.5 weight % of the composition.

10. (twice amended) The composition of Claim 9 comprising (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-

thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) or a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and another HIV protease inhibiting compound selected from the group consisting of:

(2S, 3S, 5S)-2-(2,6Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl]-amino-1,6-diphenylhexane;

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);

5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;

1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)- 3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide;

5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;

[1S-[1R-(R-),2S*]]-N^{1} [3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1 -(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide;


OH
H
N
O
O
O
N
S
O
O
NH2
Ph
;


O
HO
N
N
OH
HO
OH
;


O
N
N
H2N
NH2
HO
OH
;


H
OH
H
HO
H
N
N
O
PhS
O
N
H
;


OH
OH
BocHN
H
N
NHBoc
Ph
O
N
O
O

;


O
OH
H
N
H
N
N
H
N
O
O
Ph

;


N
S
OH
Val–HN
N
N
O
O
N
H

; and


F
F
F
CH3
O
N
H
N
S
O
O
O
H3C
OH

;

or a pharmaceutically acceptable salt thereof.

11. (twice amended) The composition of Claim 9 comprising (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) or a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and another HIV protease inhibiting compound selected from the group consisting of:

(2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3-hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl-butanoyl)- amino-1,6-diphenylhexane,

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir),

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir),



(nelfinavir),



and



(tipranavir);

or a pharmaceutically acceptable salt thereof.

14. (twice amended) The composition of Claim 1 which comprises:

(a) solubilized (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) in an amount of from about 1 to about 30 weight % of the composition;

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an amount of from about 30 to about 75 weight % of the composition and (2) ethanol in an amount of from about 3 to about 12 weight % of the composition; and

(c) water in an amount of from about 0.4 to about 3.5 weight % of the composition; and

(d) polyoxyl 35 castor oil in an amount of from about 0 to about 20 weight % of the composition.

15. (twice amended) A pharmaceutical composition comprising:

(a) (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) in an amount of about 10 weight % of the composition;

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an amount of from about 70 to about 75 weight % of the composition; and (2) ethanol in an amount of from about 3 to about 12 weight % of the composition;

(c) water in an amount of from about 0.4 to about 1.5 weight % of the composition; and

(d) polyoxyl 35 castor oil in an amount of about 6 weight % of the composition.

17. (twice amended) The composition of Claim 1 which comprises:

(a) a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl)- amino-1,6--diphenylhexane in an amount of from about 1 to about 45 weight % of the composition;

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an amount of from about 30 to about 75 weight % of the composition and (2) propylene glycol in an amount of from about 1 to about 15 weight % of the composition; and

(c) water in an amount of from about 0.4 to about 3.5 weight % of the composition.

18. (twice amended) The composition of Claim 17 which comprises:

(a) a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl) amino-1,6-diphenylhexane in an amount of from about 1 to about 45 weight % of the composition;

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an amount of from about 70 to about 75 weight % of the composition; and (2) propylene glycol in an amount of from about 1 about 8 weight % of the composition;

(c) water in an amount of from about 0.4 to about 1.5 weight % of the composition; and